Coloplast AS Class B
COLO B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| B%g | LOCK|!r&v | LOCK|XSY?&@h |
Coloplast Earnings: Revised 2030 Targets in Line With Our Expectations; Maintain Fair Value Estimate
Coloplast reported full-year sales growth of 4% and an EBIT decline of 3%, roughly matching our forecasts. The company trimmed its 2030 guidance on pricing, inflation, and US reimbursement pressure, now aligning with our expectations.
